JP2015511604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511604A5 JP2015511604A5 JP2015500545A JP2015500545A JP2015511604A5 JP 2015511604 A5 JP2015511604 A5 JP 2015511604A5 JP 2015500545 A JP2015500545 A JP 2015500545A JP 2015500545 A JP2015500545 A JP 2015500545A JP 2015511604 A5 JP2015511604 A5 JP 2015511604A5
- Authority
- JP
- Japan
- Prior art keywords
- acute lymphoblastic
- composition
- lymphoblastic leukemia
- leukemia
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 230000000719 anti-leukaemic effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610722P | 2012-03-14 | 2012-03-14 | |
| US61/610,722 | 2012-03-14 | ||
| PCT/US2013/030748 WO2013138430A1 (en) | 2012-03-14 | 2013-03-13 | Compounds and methods for treating leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511604A JP2015511604A (ja) | 2015-04-20 |
| JP2015511604A5 true JP2015511604A5 (enExample) | 2016-03-10 |
| JP6424155B2 JP6424155B2 (ja) | 2018-11-14 |
Family
ID=49161751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500545A Active JP6424155B2 (ja) | 2012-03-14 | 2013-03-13 | 白血病を治療するための化合物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9315481B2 (enExample) |
| EP (1) | EP2825162B1 (enExample) |
| JP (1) | JP6424155B2 (enExample) |
| KR (1) | KR20140136436A (enExample) |
| CN (2) | CN104244934A (enExample) |
| AU (1) | AU2013232208B2 (enExample) |
| CA (1) | CA2865437A1 (enExample) |
| ES (1) | ES2689665T3 (enExample) |
| IL (1) | IL234273A (enExample) |
| MX (1) | MX356102B (enExample) |
| RU (1) | RU2672553C2 (enExample) |
| WO (1) | WO2013138430A1 (enExample) |
| ZA (1) | ZA201406172B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3520860A1 (en) * | 2011-05-26 | 2019-08-07 | Indiana University Research & Technology Corporation | Quinone compounds for treating ape1 mediated diseases |
| WO2016186853A1 (en) | 2015-05-21 | 2016-11-24 | Indiana University Research & Technology Corporation | Methods of targeting ape1/ref-1 to inhibit hypoxia signaling genes |
| CA3051590A1 (en) * | 2017-01-25 | 2018-08-02 | Indiana University Research And Technology Corporation | Prophylaxis and treatment of acute myeloid leukemia |
| JP2020514349A (ja) * | 2017-03-20 | 2020-05-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| JPWO2003024913A1 (ja) * | 2001-09-17 | 2004-12-24 | 第一サントリーファーマ株式会社 | ＮＦ−κＢ阻害作用を有する置換安息香酸誘導体 |
| AU2003246100A1 (en) * | 2002-06-28 | 2004-01-19 | Nippon Shinyaku Co., Ltd. | Amide derivative |
| FR2900150B1 (fr) * | 2006-04-25 | 2012-07-06 | Fluofarma | Composes de type 1,4-naphtoquinones, compositions les comprenant et utilisation de ces composes en tant qu'agent anti-cancereux |
| RU2482877C2 (ru) * | 2006-12-11 | 2013-05-27 | Дженентек, Инк. | Композиции и способы для лечения опухоли |
| JP5628674B2 (ja) * | 2007-09-26 | 2014-11-19 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | キノン誘導体、医薬組成物、およびそれらの使用 |
| CN104666286A (zh) * | 2007-11-21 | 2015-06-03 | 印第安纳大学研究及科技有限公司 | 苯醌衍生物e3330联合化疗剂用于治疗癌症和血管生成 |
| SI2252597T1 (sl) * | 2008-02-01 | 2014-07-31 | Akinion Pharmaceuticals Ab | Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze |
| EP3520860A1 (en) | 2011-05-26 | 2019-08-07 | Indiana University Research & Technology Corporation | Quinone compounds for treating ape1 mediated diseases |
| WO2012167122A1 (en) | 2011-06-03 | 2012-12-06 | Indiana University Research And Technology Corporation | Compounds, compositions and methods for treating oxidative dna damage disorders |
-
2013
- 2013-03-13 AU AU2013232208A patent/AU2013232208B2/en active Active
- 2013-03-13 RU RU2014141152A patent/RU2672553C2/ru not_active IP Right Cessation
- 2013-03-13 EP EP13761860.9A patent/EP2825162B1/en active Active
- 2013-03-13 CN CN201380013870.6A patent/CN104244934A/zh active Pending
- 2013-03-13 WO PCT/US2013/030748 patent/WO2013138430A1/en not_active Ceased
- 2013-03-13 KR KR20147024023A patent/KR20140136436A/ko not_active Ceased
- 2013-03-13 ES ES13761860.9T patent/ES2689665T3/es active Active
- 2013-03-13 CA CA2865437A patent/CA2865437A1/en not_active Abandoned
- 2013-03-13 CN CN201811324380.9A patent/CN109602734A/zh active Pending
- 2013-03-13 JP JP2015500545A patent/JP6424155B2/ja active Active
- 2013-03-13 US US14/384,814 patent/US9315481B2/en active Active
- 2013-03-13 MX MX2014010275A patent/MX356102B/es active IP Right Grant
-
2014
- 2014-08-21 ZA ZA2014/06172A patent/ZA201406172B/en unknown
- 2014-08-24 IL IL234273A patent/IL234273A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| WO2016064082A3 (ko) | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 | |
| JP2016508134A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| WO2014078778A3 (en) | Antiviral azasugar-containing nucleosides | |
| JP2016515561A5 (enExample) | ||
| HK1224296A1 (zh) | 布罗莫结构域抑制剂 | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| WO2013163244A8 (en) | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation | |
| JP2015504081A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| NZ762034A (en) | Human plasma kallikrein inhibitors | |
| WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| WO2015021358A3 (en) | Compounds and methods for inhibiting phosphate transport | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| MX2014012741A (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activado de proteasa (par4) para tratamiento de agregacion plaquetaria. | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| JP2015500225A5 (enExample) | ||
| PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| TN2016000556A1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| EP3590498A4 (en) | PREPARATION WITH INCLUDING COMPLEX OF VARENICLINE OR PHARMACEUTICAL SAFE SALT THEREOF FOR ORAL ADMINISTRATION | |
| JP2016539157A5 (enExample) | ||
| CN109689652A (zh) | 稠杂环类衍生物、其制备方法及其在医学上的应用 |